F Buccisano
Overview
Explore the profile of F Buccisano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maurillo L, Spagnoli A, Candoni A, Papayannidis C, Borlenghi E, Lazzarotto D, et al.
Leuk Res
. 2023 Feb;
127:107040.
PMID: 36801702
We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreated AML, diagnosed according to WHO criteria. In the two groups, we evaluated complete remission (CR),...
2.
Buccisano F, Maurillo L, Schuurhuis G, Del Principe M, Di Veroli A, Gurnari C, et al.
Semin Hematol
. 2019 Mar;
56(2):125-130.
PMID: 30926088
Despite the increasing knowledge of the genomic landscape of acute myeloid leukemia (AML), prediction merely based on genetics fails to anticipate outcome, presumably due to the heterogeneous composition of the...
3.
Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, et al.
Leuk Res
. 2018 Jul;
71:89-91.
PMID: 30029156
No abstract available.
4.
Buccisano F, Maurillo L, Piciocchi A, Del Principe M, Picardi A, Cerretti R, et al.
Bone Marrow Transplant
. 2016 Dec;
52(3):473-475.
PMID: 27941782
No abstract available.
5.
Del Poeta G, Postorino M, Pupo L, Del Principe M, Dal Bo M, Bittolo T, et al.
Drugs Today (Barc)
. 2016 Jun;
52(4):249-60.
PMID: 27252989
Venetoclax (ABT-199) is a small-molecule selective oral inhibitor of the antiapoptotic protein Bcl-2 that promotes programmed cell death of chronic lymphocytic leukemia (CLL) cells regulating the release of proapoptotic factors,...
6.
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy
Postorino M, Pupo L, Provenzano I, Del Principe M, Buccisano F, Franceschini L, et al.
Ann Hematol
. 2015 Oct;
95(1):153-154.
PMID: 26442854
No abstract available.
7.
Caocci G, Voso M, Angelucci E, Stauder R, Cottone F, Abel G, et al.
Leuk Res
. 2015 Jun;
39(8):859-65.
PMID: 26120100
Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in...
8.
Buccisano F, Maurillo L, Piciocchi A, Del Principe M, Sarlo C, Cefalo M, et al.
Ann Hematol
. 2015 Apr;
94(8):1319-26.
PMID: 25869029
In the present analysis, we evaluated whether in elderly acute myeloid leukemia (AML) patients (>60 years), minimal residual disease (MRD) assessed by flow cytometry may have a role in guiding...
9.
Monteleone F, Buccisano F, Boffa L, Buttari F, Di Veroli A, Borriello G, et al.
Mult Scler
. 2014 Sep;
21(2):257-8.
PMID: 25186208
No abstract available.
10.
Zeitani J, Buccisano F, Nardella S, Flaminio M, Prati P, Chiariello G, et al.
Perfusion
. 2013 Feb;
28(4):298-305.
PMID: 23411504
Hemostasis is impaired during CABG and coagulation abnormalities often result in clinically relevant organ dysfunctions, eventually increasing morbidity and mortality rates. Fifteen consecutive patients with coronary artery disease submitted to...